Key Highlights

● Ionis plunged on November 9 after cutting its Tryngolza sales forecast.

● The company now expects about $50 million this year.

● The prior range was $100 million to $110 million.

● The cut reflects a slower launch.

A forecast cut that stung

Ionis Pharmaceuticals (NASDAQ:IONS) plunged on Monday, November 9, 2026, after cutting its 2026 sales forecast for Tryngolza, one of its newest medicines. The company now expects about $50 million in Tryngolza sales this year, down from a previous range of $100 million to $110 million, citing a slower launch, according to news reports.

The stock fell steeply in early trading, with a mid-morning reading showing a particularly deep drop and another putting the price at $28.61. By early afternoon, a reading showed a somewhat smaller decline.

Good results, bad headline

The plunge came despite a strong quarter overall. Ionis reported third-quarter Revenue that rose by more than half from a year earlier, along with a smaller-than-expected adjusted operating loss, according to market coverage.

But investors focused on Tryngolza. Cutting a forecast roughly in half signals that uptake of the drug is running well behind the company's earlier expectations, and that shifted attention away from the otherwise solid numbers.

What Tryngolza is

Tryngolza, also known as olezarsen, is designed to lower triglycerides, a type of fat in the blood. It was approved to treat familial chylomicronemia syndrome, a rare genetic disorder that causes extremely high triglyceride levels and can lead to painful and dangerous inflammation of the pancreas. Ionis develops medicines based on RNA-targeting technology, and Tryngolza is an important part of its push to sell more of its own drugs directly rather than relying mainly on partners.

Launching a drug for a rare disease can be challenging. Patients must be diagnosed, doctors must become familiar with the treatment and insurers must agree to cover it. Any of those steps can take longer than expected.

For investors, the forecast cut also changes the math on the company's commercial ambitions. Early launch trends are often used to estimate a drug's eventual peak sales, so a slower start can lead analysts to lower long-term projections, not just this year's figure. That helps explain why the stock reaction was so severe relative to the size of the near-term revenue shortfall.

Biotech's mixed day

Ionis was far from the only drugmaker moving on its own news. Other biotech stocks also fell on company-specific developments: ImmunityBio (NASDAQ:IBRX) slid despite strong sales growth, while Faeth Therapeutics (NASDAQ:FTH) and Zura Bio (NASDAQ:ZURA) tumbled on trial results. Arrowhead Pharmaceuticals (NASDAQ:ARWR), another RNA-focused drug developer, also fell sharply, though no company-specific news was found for it.

The broader market moved the other way. The Nasdaq Composite surged 673.71 points to 25,253.14, its best day since July 30, and the S&P 500 climbed 173.08 points to 7,549.94. All 11 S&P 500 sectors rose as oil slid on hopes for a US-Iran peace deal.

Launch Trends Drive Estimates

The key question is whether Tryngolza's launch can pick up speed. Investors will look for updates on how many patients start treatment, insurance coverage trends and whether Ionis can meet its reduced forecast. Comments on what is slowing the launch will be important in judging whether the problem is temporary.

The broader Ionis pipeline also matters, since the company has other drugs in development and on the market. Analysts may revise their estimates after the forecast cut. On the macro side, Tuesday's October Consumer Price Index is the last Inflation report before the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected.